Executive Summary
A US national cohort of patients aged 60 or younger shows SAVR beats TAVR on 5-year mortality (HR 0.58) and across nearly every cardiac endpoint — reintervention, pacemaker, paravalvular leak, endocarditis, MI — hardening rather than softening the ESC 2025 line that patients under 70 with low surgical risk belong on a surgeon's table. A single-center JTCVS Open series of 414 large-annulus AVRs adds that heart failure rehospitalization runs five-fold higher after TAVR than SAVR even after adjustment, while an OCEAN-TAVI decade-long registry confirms 30-day stroke has not budged in Asian TAVR practice despite falling PPM and PVL rates. Together, today's data tightens the case against reflexive TAVR in younger and anatomically complex patients — and reopens a question the guidelines are already split on.
- SAVR reduced 5-year mortality by 42% versus TAVR in patients ≤60, with matched cohorts of 1,666 each (TriNetX cohort, JTCVS Open).
- Heart failure rehospitalization was 5-fold higher post-TAVR than post-SAVR in large/extra-large annuli, HR 5.09 after adjustment (single-center, N=414).
- A patient-specific finite-element model predicts THV underexpansion pre-procedurally and quantifies postdilatation gains, with expansion errors under 5% for balloon-expandable valves (Structural Heart).
- Complete revascularization in complex PCI + TAVI cut 1-year CV rehospitalization (HR 0.61) without a mortality signal across 550 patients at 14 centers (ASCoP Registry).
- A novel bovine pericardial valve used off-label for tricuspid replacement showed 15.9% 30-day mortality and 92% 4-year freedom from reintervention in high-risk patients (JTCVS Open).
What to watch: Cedars-Sinai's newly recruiting TAVR vs SAVR in Severe Bicuspid Aortic Stenosis trial (NCT07413965, N=1,200) — the first adequately powered randomized comparison in BAV, an anatomy where both guidelines still hedge.
Aortic Valve (TAVR/TAVI)
[NOTABLE] The under-60 TAVR case took a serious hit. Jishu and colleagues pulled 9,841 patients aged ≤60 from TriNetX between 2006 and 2025, matched 1,666 per arm on age, sex, BAV, comorbidities, and prior cardiac surgery, and found SAVR halved 5-year mortality (HR 0.58, 95% CI 0.48–0.69) and cut reintervention, PPM, PVL, endocarditis, and complete AV block by 35–61%. This is retrospective administrative data with all attendant confounding — TriNetX cannot capture anatomic contraindications to SAVR — but the effect sizes are large and directionally consistent. Both guidelines already reserve SAVR for younger patients: ACC/AHA 2020 recommends SAVR below age 65 (Class I); ESC 2025 recommends SAVR below age 70 at low surgical risk (Class I). Today's data hardens that floor rather than eroding it.
In large and extra-large annuli, Jacquemyn's Pittsburgh series (N=414, 353 TAVR vs 61 SAVR) reports comparable 30-day mortality but a 5-fold adjusted excess of heart failure rehospitalization after TAVR (HR 5.09). Single-center, retrospective, and heavily confounded by age (TAVR median 80.2 vs SAVR 68.0), but the standardized mortality ratio for TAVR was 1.69 versus 0.29 for SAVR against an age/sex-matched US population — a gap the authors themselves attribute to selection, not device. ESC 2025 notes that patient-prosthesis mismatch risk rises with large annuli and favors SAVR with root enlargement when mismatch is predicted.
OCEAN-TAVI's decade of 13,245 Asian TAVR patients delivers a mixed report: PPM and mild-or-greater PVL fell substantially with balloon-expandable valves, but risk-adjusted 30-day stroke did not move. Stroke remains the unmet complication that cerebral embolic protection has not solved at scale — a finding directly relevant to Boston Scientific's SENTINEL franchise, which has not demonstrated mortality or stroke benefit in randomized data.
The ASCoP Registry (550 CHIP+TAVI patients, 14 centers) found complete revascularization reduced 1-year CV rehospitalization (HR 0.61) without a mortality benefit — a hospitalization signal, not a hard outcome. Retrospective, non-randomized. A Japanese multimarker AKI model incorporating eGFR, urinary L-FABP, clusterin, and CRP discriminated post-TAVI AKI with AUC 0.85 in a small single-center cohort (N=186, 24 events); external validation is needed before clinical deployment.
Mitral Valve (MitraClip, PASCAL, TMVR)
3D vena contracta area is being pushed as a baseline and post-TEER quantification standard, with Kim and colleagues reporting on its clinical performance in JASE. No abstract is available, so judgment on how it performs against 3D PISA and quantitative Doppler must wait. The field's persistent problem is that MR grading after TEER is notoriously unreliable, and any improvement over color-flow eyeballing matters directly for the ESC 2025 Class I indication for TEER in ventricular SMR — where residual MR grade drives both the procedural endpoint and longer-term outcomes.
A dual-orifice mitral bioprosthesis designed to address LVOT obstruction in large annuli produced proof-of-concept ovine data: EOAs of 2.0–2.7 cm² across sizes, stable mean gradients at 20 weeks, one transcatheter implantation followed 125 days. Six sheep. LVOT obstruction remains the primary anatomic gatekeeper for TMVR at scale, so any design that meaningfully changes that calculus deserves tracking — but ovine models overstate what will hold up in calcified human annuli, and ESC 2025 rates TMVR for degenerative MS with MAC at Class IIb only, at experienced centers.
Tricuspid Valve (TriClip, TTVR)
A Montreal series of 82 patients undergoing TVR with a new bovine pericardial bioprosthesis used off-label reported 15.9% 30-day mortality, 63% 4-year survival, 92% freedom from reintervention, and 19.3% new pacemaker implantation. These are sobering numbers, but the population is high-risk by design (mean TRI-SCORE 11.8, 65% NYHA III/IV, 11% for prior TriClip failure). Two patients (2.6%) developed severe central intraprosthetic TR at 2 years — a durability signal that warrants longer follow-up. ESC 2025 upgraded transcatheter TR treatment to Class IIa based on TRILUMINATE and TRISCEND II, but surgical TVR remains the standard for lower-risk symptomatic primary TR under ESC 2025 Class I — this bioprosthesis occupies the space between those two poles, where high-risk patients are too sick for conventional surgery but may not be well served by repair-based transcatheter options. If durability holds past 5 years, it fills a real gap where undersized valves and pannus formation have plagued conventional prostheses in the tricuspid position.
Surgical vs. Transcatheter Comparisons
Two head-to-head data drops today, both favoring surgery, both retrospective. The under-60 TriNetX analysis is the more consequential because it directly tests the youngest cohort where TAVR indication creep has been most aggressive — and finds a mortality gap that widens over 5 years. The large-annulus Pittsburgh series is confounded by a 12-year age gap between arms, but the HF rehospitalization signal (HR 5.09) is too large to dismiss even accounting for baseline risk. Neither is randomized. The bicuspid RCT (NCT07413965) is what will actually settle a piece of this — and it is now recruiting.
Device & Technology
Akodad and colleagues used patient-specific finite element modeling on pre-TAVI CT to predict THV underexpansion with 3–9% error and forecast the yield of postdilatation. Sample sizes are small and the workflow is not clinically deployable at scale, but the concept — pre-procedural simulation of the specific patient's specific valve to identify who will underexpand and by how much — is where TAVI planning is heading. Underexpansion drives elevated gradients, PVL, and HALT; the field has treated postdilatation as reactive rather than planned. An accompanying editorial by Trimaille frames this as a step toward durability — the dimension of TAVI performance where ESC 2025 explicitly cautions that long-term data beyond 10 years remain limited.
Financial Analysis
Institutional accumulation in Edwards Lifesciences dominated the tape, with ABN AMRO taking a fresh $83.6M position and AMG National Trust adding $6.8M, alongside multiple smaller allocators. EW is up 16.8% over six months against MDT flat and BSX down 32%. The buy-side is pricing TAVR volume growth, EARLY TAVR-driven asymptomatic expansion, and the tricuspid pipeline (EVOQUE) — not today's SAVR data. That dislocation is precisely the setup where clinical evidence and market narrative diverge. If the under-60 mortality signal survives replication, the growth math on TAVR expansion into younger cohorts gets substantially less comfortable.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close $91.60, down 1.04% on the day; +16.76% over 6 months
- Market cap $52.7B; trailing P/E 54.5, forward P/E 27.1; beta 0.85; 52-week range $72.30–$96.29
- Analyst target $100.96 (26 analysts, range $84–$110); consensus buy
- Next earnings 2026-10-29; EPS est $0.74, revenue est $1.68B
- The pure-play TAVR/mitral/tricuspid name. Six-month strength reflects EARLY TAVR trial tailwind and EVOQUE TTVR launch momentum. Today's SAVR-favoring data doesn't hit the near-term thesis but complicates the low-risk/young-patient expansion story that supports the forward multiple.
Medtronic (MDT)
- Close $91.27, up 0.76%; -3.70% over 6 months
- Market cap $116.8B; trailing P/E 24.5, forward P/E 14.2; beta 0.57; 52-week range $73.31–$106.33
- Analyst target $98.44 (25 analysts); consensus buy
- Next earnings 2026-09-01; EPS est $1.39, revenue est $9.55B
- Evolut franchise continues to hold market share, but OCEAN-TAVI data showing balloon-expandable valves lead on PPM/PVL reduction over the decade is a competitive headwind Medtronic has been fighting with each Evolut iteration.
Abbott (ABT)
- Close $111.25, essentially flat; +0.43% over 6 months
- Market cap $193.8B; trailing P/E 36.0, forward P/E 18.4; beta 0.58; 52-week range $81.97–$137.49
- Analyst target $119.40 (25 analysts); consensus buy
- Next earnings 2026-10-14; EPS est $1.42, revenue est $12.99B
- MitraClip and TriClip are the structural relevance here. ESC 2025's Class I upgrade for TEER in ventricular SMR remains the durable tailwind.
Boston Scientific (BSX)
- Close $51.83, up 0.27%; -32.06% over 6 months
- Market cap $75.1B; trailing P/E 21.0, forward P/E 15.1; beta 0.57; 52-week range $42.20–$109.50
- Analyst target $62.69 (29 analysts); consensus buy
- Next earnings 2026-10-28; EPS est $0.81, revenue est $5.26B
- The steep six-month drawdown reflects broader concerns beyond structural heart — but the ACURATE neo2 US pathway and the SENTINEL cerebral embolic protection franchise (directly relevant given OCEAN-TAVI's unchanged stroke rate finding) remain the structural exposure.
Anteris Technologies (AVR.AX)
- Close A$13.00, up 7.44% on the day; +62.30% over 6 months
- Market cap A$1.3B; forward P/E -6.0 (pre-revenue); 52-week range A$5.20–A$15.47
- Single analyst target A$13.00; consensus hold
- DurAVR single-piece bovine pericardial TAVR platform. The 6-month rip reflects early clinical results and IDE progression. Speculative on execution and regulatory timeline.
Market outlook: Today's clinical data — SAVR mortality advantage under 60, HF rehospitalization signal in large annuli — creates a narrative headwind for TAVR volume expansion into younger and anatomically complex patients. That directly touches Edwards' and Medtronic's incremental growth math. Institutional flows into EW signal the buy-side is not repricing on evidence risk today. The gap between clinical caution and market enthusiasm continues to widen.
Clinical Trial Updates
Aortic
- [LANDMARK] NCT07413965 — TAVR vs SAVR in Severe Bicuspid Aortic Stenosis. Status: RECRUITING. Phase: NA. Enrollment: 1,200. Sponsor: Cedars-Sinai Medical Center. Last updated 2026-08-14. The first adequately powered randomized head-to-head in BAV — the anatomy where both ACC/AHA 2020 (Class IIb TAVI for BAV) and ESC 2025 (Class IIb TAVI in BAV at increased surgical risk) explicitly hedge. NOTION 2's 100-patient BAV subgroup hinted at higher TAVR event rates. If Cedars-Sinai enrolls to 1,200 and follows past 3 years, this trial redefines the BAV recommendation in the next guideline cycle.
What next: The bicuspid RCT is the most consequential trial in structural heart to enter recruitment this year — but with a 1,200-patient target, meaningful readouts are years out. Between now and then, watch for the next ACC/AHA update to reconcile the ESC 2025 shift toward TAVI at age 70 against today's growing retrospective SAVR advantage in the young.